Blog

  • Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

    Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

    Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026

    Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028

    Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene

    Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028

    CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced program and financial updates at its Analyst Day event. The updates include mRNA pipeline progress and a three-year plan for strategic growth.

    “Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics,” said Stéphane Bancel, CEO of Moderna. “We plan to deliver up to 10 percent revenue growth in 2026 while continuing to reduce our R&D investments and diversify further into oncology. Our financial outlook remains strong, and we are focused on disciplined execution as we advance our pipeline and bring innovative mRNA medicines to patients around the world.”

    Business Strategy & Commercial Growth Drivers

    Over the near term, Moderna will continue to build a large seasonal vaccine franchise targeting at-risk populations and propelling the Company to 2028 cash breakeven. The Company expects to invest the cash generated from its marketed products, Spikevax®, mRESVIA® and mNEXSPIKE®-as well as from anticipated launches of influenza, flu/COVID combination and Norovirus vaccines-into its oncology and rare disease programs. Investments in late-stage oncology and rare disease programs set the stage for additional growth in 2027 and 2028, with early-stage pipeline investments expected to mature in 2029 and beyond.

    Commercial growth drivers include geographic expansion and new product launches. In 2026, the Company expects growth from the annualized impact of long-term partnerships in the UK, Canada and Australia that enhance research and development (R&D) investment, support national security and defense, and provide revenue visibility through onshore manufacturing. The Company also expects continued strong uptake of mNEXSPIKE in the U.S. and its launch in other countries.

    In 2027, Europe represents a significant market for respiratory virus vaccines, as a competitor COVID contract lapses and more product approvals are expected. New potential long-term partnerships in Latin America and Asia-Pacific, as well as entry into the flu vaccine market, also position the Company for further expansion.

    In 2028, Moderna anticipates a first-to-market flu/COVID combination vaccine and continued momentum with a potential novel Norovirus vaccine, expanding its seasonal franchise to as many as six approved products.

    The Company’s existing commercial infrastructure supports these seasonal vaccine growth drivers. A focused Moderna U.S. commercial team engages the same customers across the retail pharmacy, government and healthcare provider (IDN) channels, and teams supporting the UK, Canada and Australia partnerships are established. Additionally, Moderna’s EU commercial infrastructure is in place and targeted investments will be made as needed.

    Global Production Network

    Since 2022, Moderna has streamlined its production sites into a global manufacturing network ready for new launches and delivering products for multi-year strategic partnerships. The Company exited eight contract manufacturers, announced new drug product capabilities in the U.S., and added three Moderna-built and managed facilities in the UK, Canada and Australia. Increased volume, manufacturing efficiency and waste reduction across Moderna sites is expected to drive a projected 10% improvement in gross margins over the next three years.

    In the U.S., Moderna’s facility in Norwood, Massachusetts, enables scalable, end-to-end production by incorporating automation, robotics and AI to increase cost efficiency and reduce waste. The addition of new fill/finish capabilities in 2027 will provide end-to-end control and flexibility with greater speed.

    Three new global sites in Laval, Canada; Harwell, UK; and Clayton, Australia enable local access to mRNA medicines and drive revenue diversification. These manufacturing facilities position the Company to deliver cost-optimized growth with margins consistent with U.S. operations.

    The Marlborough, Massachusetts, facility was purpose-built for Moderna’s individualized neoantigen therapy, intismeran. Designed for speed and scalability with advanced automation and robotics, the site began clinical batch supply in September 2025 and is on track for commercial launch as the Company methodically right-sizes the intismeran manufacturing process to improve turnaround time and reduce costs.

    Pipeline Progress

    Highlights from Moderna’s approved vaccines and prioritized portfolio include:

    Seasonal Vaccines

    • Spikevax (mRNA-1273, COVID-19 vaccine): Approved in 40 countries.

    • mNEXSPIKE (mRNA-1283, COVID-19 vaccine): Approved in the U.S. and Canada. The Company has filed and is targeting 2026 approvals in Australia, the EU, Japan and Taiwan.

    • mRESVIA (mRNA-1345, RSV vaccine): Approved in 40 countries for adults aged 60 and older, and in 31 of those countries for adults 18-59 at increased risk for RSV disease.

    • mRNA-1010 (Seasonal Influenza vaccine): Moderna expects to complete submissions for approval of mRNA-1010 in the U.S., EU, Canada and Australia by January 2026.

    • mRNA-1083 (Seasonal flu + COVID combination vaccine): The Company’s mRNA-1083 filing is under review with the European Medicines Agency (EMA).Moderna submitted for approval to Health Canada in 2025. The Company is awaiting further guidance from the U.S. FDA on refiling.

    • mRNA-1403 (Norovirus vaccine): The ongoing Phase 3 study has not accrued sufficient cases and is enrolling a second Northern Hemisphere season (2025-2026) for additional case accruals, which will inform the timing of the Phase 3 readout. Moderna expects an interim analysis in 2026.

    Oncology Therapeutics

    • mRNA-4157 (Intismeran autogene): Advancing in collaboration with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma.

    • mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic NSCLC.

    Rare Disease Therapeutics

    • mRNA-3927 (Propionic Acidemia therapeutic): Reached target enrollment in a registrational study.

    • mRNA-3705 (Methylmalonic Acidemia therapeutic): Selected for the U.S. FDA’s START program, with a registrational study expected to begin in 2026.

    For more details on the data and programmatic updates shared during Moderna’s Analyst Day investor event today, please visit “Events and Presentations” in the Investors section of the Moderna website.

    Programs Discontinued

    Based on the Company’s strategic prioritization, four programs in its pipeline are discontinued:

    • mRNA-1647: The Company is discontinuing its congenital Cytomegalovirus (CMV) clinical development program. Moderna will continue to evaluate mRNA-1647 in an ongoing Phase 2 trial of bone marrow transplant patients.

    • mRNA-1608: The Company’s herpes simplex virus (HSV) clinical development program will not advance to Phase 3.

    • mRNA-1468: The Company’s Varicella-Zoster virus (VZV) clinical development program will not advance to Phase 3.

    • mRNA-3745: The Company’s Glycogen Storage Disease Type 1a (GSD1a) clinical development program will not advance to Phase 2.

    Financial Updates

    Moderna expects up to 10% revenue growth in 2026, driven by the annualized impact of its long-term partnerships with the UK, Canada and Australia and continued strong uptake of mNEXSPIKE in the U.S. and launches in other countries. In addition, the Company has multiple growth opportunities in 2027 and beyond.

    The Company is reducing its 2026 and 2027 expected cash costs to approximately $4.2 billion and a range of $3.5 to $3.9 billion, respectively. Moderna will achieve this through disciplined cost management and R&D prioritization, while manufacturing improvements are projected to improve gross margins by more than 10 percentage points over the next three years.

    Moderna is increasing its R&D investment allocation in oncology and rare diseases as large infectious disease investments conclude. The Company’s balance sheet sufficiently funds its investments through targeted cash breakeven in 2028.

    Today, Moderna announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds. The non-dilutive financing bolsters the Company’s strong balance sheet and provides increased flexibility. Moderna remains confident in its strong financial framework with enhanced liquidity and today updated its 2025 projected year-end cash and investment balance to a range of $7.1 to $7.6 billion, tied to the $0.6 billion initial loan draw and increased from previous expectations of $6.5 to $7.0 billion.

    About Moderna

    Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

    With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

    Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s anticipated commercial growth drivers, including geographic expansion and new product launches; Moderna’s ability to achieve up to 10% revenue growth in 2026; Moderna’s ability to expand its seasonal vaccine franchise to up to six approved products by 2028; anticipated clinical readouts for Moderna’s oncology pipeline; Moderna’s 2026 and 2027 expected GAAP operating expenses; Moderna’s continued cost management and R&D prioritization and ability to reduce cash costs; Moderna’s balance sheet and targeted cash breakeven in 2028; Moderna’s 2025 projected year-end cash and investment balance; Moderna’s investments in its oncology and rare disease programs; additional growth in 2027-2028; anticipated strong update of mNEXSPIKE in 2026; Moderna’s global production network; the expectation that manufacturing improvements will improve gross margins over the next three years; anticipated regulatory filings and potential approvals; and anticipated milestones for Moderna’s pipeline programs. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    ###

    Moderna Contacts

    Media:
    Chris Ridley
    Head, Global Media Relations
    +1 617-800-3651
    Chris.Ridley@modernatx.com

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire

  • ATHA Energy Confirms New High-Grade Discovery at Angilak Project – Rib North, Maiden Hole Returns Assays with 34.7 m of Total Composite Uranium Mineralization, Including 13.6 m Grading 0.53% U3O8, 1.1 m Grading 4.81% U3O8, and Grades Up to 8.16% U3O8

    ATHA Energy Confirms New High-Grade Discovery at Angilak Project – Rib North, Maiden Hole Returns Assays with 34.7 m of Total Composite Uranium Mineralization, Including 13.6 m Grading 0.53% U3O8, 1.1 m Grading 4.81% U3O8, and Grades Up to 8.16% U3O8

    HIGHLIGHTS

    • Assays confirm the Company’s maiden drillhole, RIBN-DD-001, at the RIB North Discovery as the best exploration hole drilled to date at the Angilak Uranium Project;

    • RIBN-DD-001 assays returned total composite uranium mineralization1 of 34.7 m encompassing seven zones from 287.0 m to 439.9 m (Figure 4) – surpassing what was reported in the release of preliminary results (September 23rd, 2025, News Release);

    • The widest continuous intersection in the hole – from 426.3 to 439.9 – returned 13.6 m of composite uranium mineralization1 grading 0.53% U3O8, including 1.1 m grading 4.81% U3O8 with the highest-grade sample returning 8.16% U3O8 over 0.5 m;

    • Mineralization was first intersected in the sandstone over three intervals (between 287.0 m and 351.1 m). The fourth zone was intersected directly above the unconformity (located at 356.7m), extending into graphitic basement rock below. The additional three widest intersections are basement hosted vein style uranium mineralization, associated with strong hematite alteration, graphitic structures and overprinting silicification – similar in style and widths observed in Athabasca Basin basement hosted deposits;

    • RIB North Discovery is situated along the 4.4 km eastern limb of the Mineralized RIB Corridor (“MRC”) – a 12 km trend containing stacked structural anomalies, identified using 3D EM Inversion modeling. During the 2025 Angilak Exploration Program these anomalies were drill tested, resulting in a 100% success rate of intersecting uranium mineralization, and the discovery of four new mineralized areas: RIB East, West, North and South (Figures 2 & 3);

    • The nearest drilling to RIBN-DD-001 occurred ~1.4 km along strike at the RIB East Discovery and 1.8 km along strike at the RIB West Discovery areas – both holes intersected uranium mineralization, however, the extension of the structural corridor hosting RIB North mineralization remains untested and highly prospective (Figures 3);

    • All 2025 mineralized drill core samples have been submitted to the Saskatchewan Research Council (SRC) Geoanalytical Laboratory for analysis. The Company anticipates disclosing all remaining assay results within Q4 2025.

    Troy Boisjoli, CEO commented: “During my career as an exploration geologist I have had the pleasure of working in some of the world’s premier regions for discovery of uranium mineralization – such as the Patterson Lake and Rabbit Lake corridors. With that experience, I cannot recall a maiden hole into a target area that returned of an intersection this significant, with assays surpassing our expectations. The grades and thicknesses, the style of mineralization, along with the pathfinder elements and geophysical signatures are all present at the RIB North Discovery. The confirmation of the MRC as an important corridor at the Angilak project – in addition to Lac 50 Deposit Trend, and numerous other showings – reinforces the blue-sky potential that Angikuni Basin could be the next Athabasca Basin. At a time when the Canadian Government is looking to advance mineral resource projects – and strengthen infrastructure in the north. The Angilak Uranium Project is just getting started.”

    Cliff Revering, VP Exploration added: “We are extremely pleased with the recently received assay results from RIBN-DD-001, our first drill hole into this target area, which have exceeded the extent and scale of uranium mineralization indicated by our preliminary downhole gamma probe data. Intersecting 34.7 metres of composite uranium mineralization, including a 1.1-metre interval averaging 4.81% U₃O₈, clearly demonstrates the significant scale and high-grade potential present in this zone.

    The Mineralized RIB Corridor, anchored by the results of RIBN-DD-001, represents an exciting new discovery along the RIB-Nine Iron Corridor within the Angikuni Basin and reinforces the exploration thesis we have pursued since acquiring the Angilak Project in 2024. Our 2025 drilling, combined with the 3D inversion model from the 2024 MMT survey across the northern Angikuni Basin and Lac 50 Deposit areas, has now identified numerous highly prospective trends and untested targets, positioning us for a compelling 2026 exploration campaign.

    Our conviction that the Angikuni Basin is an emerging uranium district with strong potential for additional high-grade uranium discoveries continues to grow as we advance our exploration strategy.”

    VANCOUVER, BC / ACCESS Newswire / November 20, 2025 /ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) (“ATHA” or the “Company“), is pleased to announce assay results from the maiden drillhole at the RIB North Discovery, completed as part of the 2025 Angilak Exploration Program at its 100%-owned Angilak Uranium Project in Nunavut, Canada. Assay results from RIBN-DD-001 represent the best exploration hole to date at the Angilak Project, intersecting a total of 34.7 m of composite uranium mineralization1 over seven zones, from 287 m to 439.9 m depth. The highest grade and widest continuous interval of mineralization was intersected from 426.3 to 439.9 m depth, grading 0.53% U3O8 including 8.16% U3O8 over 0.5 m (Figure 4).

    The RIB North Discovery is situated along the 4.4 km eastern limb of the Mineralized RIB Corridor (“MRC”) – a 12 km trend containing stacked structural anomalies, identified using 3D EM Inversion modeling. During the 2025 Angilak Exploration Program these anomalies were drill tested, resulting in a 100% success rate of intersecting uranium mineralization, and the discovery of four new mineralized areas: RIB East, West, North and South.

    The nearest drilling to RIBN-DD-001 occurred ~1.4 km along strike at the RIB East Discovery area and 1.8 km along strike at the RIB West Discovery area – both holes intersected uranium mineralization, however, the extension of the structural corridor hosting RIB North mineralization remains untested and highly prospective (Figures 1, 2, & 3).

    Figure 1: Angilak Project Area – 2025 Exploration Target Area (Black Rectangles), Mineralized RIB Corridor (Red Rectangles), & Mapped Historic Mineralized Showings

    Figure 2: 2025 Angilak Exploration Program – EM Inversion Model & Drill Collar Locations from MRC, along the RIB-Nine Iron Trend.

    Figure 3: 2025 Angilak Exploration Program – Isometric schematic of the MRC, displaying EM Inversion model and 2025 drilling.

    Table 1: 2025 Angilak Exploration Program Drill Collar Information

    Hole ID

    Trend

    Zone

    Azimuth (°)

    Dip (°)

    Easting (mE)

    Northing (mN)

    Elevation (m)

    Final Depth (m)

    *KU-DD-001

    RIB-Nine Iron

    KU Target

    30

    70

    515830

    6936190

    256.5

    599

    *J4R-DD-091

    Lac 50

    J4/Ray

    25

    57

    522295

    6938558

    218

    650

    *RIBE-DD-001

    RIB-Nine Iron

    RIB East

    145

    -55

    497928

    6929449

    270

    443

    *RIBE-DD-002

    RIB-Nine Iron

    RIB East

    145

    -55

    497766

    6929322

    271

    345

    *RIBE-DD-003

    RIB-Nine Iron

    RIB East

    145

    -63

    497524

    6929337

    271

    398

    *RIBE-DD-004

    RIB-Nine Iron

    RIB East

    145

    -60

    497404

    6920180

    271

    428

    *RIBE-DD-005

    RIB-Nine Iron

    RIB East

    155

    -65

    497530

    6929401

    270

    472

    *RIBE-DD-006

    RIB-Nine Iron

    RIB East

    145

    -60

    497670

    6929501

    273

    491

    *RIBE-DD-007

    RIB-Nine Iron

    RIB East

    325

    -50

    497798

    6929101

    274

    467

    *RIBE-DD-008

    RIB-Nine Iron

    RIB East

    325

    -55

    498284

    6929287

    264

    464

    *RIBW-DD-001

    RIB-Nine Iron

    RIB West

    150

    -50

    495831

    6929490

    274

    503

    *RIBW-DD-002

    RIB-Nine Iron

    RIB West

    145

    -55

    497766

    6929322

    271

    380

    *RIBW-DD-003

    RIB-Nine Iron

    RIB West

    325

    -55

    497645

    6930031

    275

    347

    *RIBN-DD-001

    RIB-Nine Iron

    RIB North

    300

    -65

    499574

    6929887

    261

    623

    *RIBS-DD-001

    RIB-Nine Iron

    RIB South

    150

    -50

    495747

    6927640

    277.5

    377

    *KU-DD-002

    RIB-Nine Iron

    KU Target

    30

    -70

    515525

    6936210

    251

    616

    *KU-DD-003

    RIB-Nine Iron

    KU Target

    30

    -70

    515758

    6936059

    268.5

    56

    *KU-DD-003A

    RIB-Nine Iron

    KU Target

    30

    -68

    515758

    6936059

    268.5

    605

    *KU-DD-004

    RIB-Nine Iron

    KU Target

    30

    -60

    515757

    695641

    255

    602

    *KU-DD-005

    RIB-Nine Iron

    KU Target

    210

    -70

    515980

    6935734

    256

    302

    *KU-DD-006

    RIB-Nine Iron

    KU Target

    30

    -70

    514794

    6935805

    275

    647

    *ML-DD-013

    Lac 50

    ML Target

    25

    -50

    523968

    6939404

    215

    551

    *ML-DD-014

    Lac 50

    ML Target

    25

    -50

    524869

    6939109

    206

    407

    *Previously released drillholes from 2025 Angilak Exploration Program

    Figure 4: Striplog RIBN-DD-001 showing mineralized interval with composite uranium mineralization1 with average grades – derived from assay samples.

    Assay Samples

    1.Composite mineralization is calculated using a 0.01% U3O8 cutoff with a maximum internal dilution of 1.5 m.

    2The Company considers high-grade mineralization to be any interval over 1% U3O8.

    All drill intercepts are core width and true thickness is yet to be determined.

    Core samples are submitted to the Saskatchewan Research Council (SRC) Geoanalytical Laboratories in Saskatoon. The SRC facility is ISO/IEC 17025:2005 accredited by the Standards Council of Canada (scope of accreditation #537). The samples are analyzed for a multi-element suite using partial and total digestion inductively coupled plasma methods, for boron by Na2O2 fusion, and for uranium by fluorimetry.

    References for Historic Diamond Drilling Results and Surficial Sampling

    3For additional information regarding ATHA’s Angilak Project please refer to the Technical Report entitled “Technical Report on the Angilak Property, Nunavut, Canada” with an effective date of October 14, 2025, prepared by Matt Batty, MSc, P. Geo, who is a “qualified person” under NI 43-101, available under ATHA’s SEDAR+ profile at www.sedarplus.ca.

    Qualified Person

    The scientific and technical information contained in this news release have been reviewed and approved by Cliff Revering, P.Eng., Vice President, Exploration of ATHA, who is a “qualified person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

    About ATHA

    ATHA is a Canadian mineral company engaged in the acquisition, exploration, and development of uranium assets in the pursuit of a clean energy future. With a strategically balanced portfolio including three 100%-owned post discovery uranium projects (the Angilak Project located in Nunavut, and CMB Discoveries in Labrador, and the newly discovered basement hosted GMZ high-grade uranium discovery located in the Athabasca Basin). In addition, the Company holds the largest cumulative prospective exploration land package (>7 million acres) in two of the world’s most prominent basins for uranium discoveries – ATHA is well positioned to drive value. ATHA also holds a 10% carried interest in key Athabasca Basin exploration projects operated by NexGen Energy Ltd. and IsoEnergy Ltd. For more information visit www.athaenergy.com.

    On Behalf of the Board of Directors

    Troy Boisjoli, CEO, ATHA Energy Corp

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    For more information, please contact:

    Troy Boisjoli
    Chief Executive Officer
    Email: info@athaenergy.com
    Website: www.athaenergy.com
    Phone: 1-(236)-521-0526

    Cautionary Statement Regarding Forward-Looking Information

    This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These forward-looking statements or information may relate to ATHA’s proposed exploration program, including statements with respect to the expected benefits of ATHA’s proposed exploration program, any results that may be derived from ATHA’s proposed exploration program, the timing, scope, nature, breadth and other information related to ATHA’s proposed exploration program, any results that may be derived from the diversification of ATHA’s portfolio, the prospects of ATHA’s projects, including mineral resources estimates and mineralization of each project, the prospects of ATHA’s business plans and any expectations with respect to defining mineral resources or mineral reserves on any of ATHA’s projects, and any expectation with respect to any permitting, development or other work that may be required to bring any of the projects into development or production.

    Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management at the time, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such assumptions include, but are not limited to, assumptions that the anticipated benefits of ATHA’s proposed exploration program will be realized, that no additional permit or licenses will be required in connection with ATHA’s exploration programs, the ability of ATHA to complete its exploration activities as currently expected and on the current anticipated timelines, including ATHA’s proposed exploration program, that ATHA will be able to execute on its current plans, that ATHA’s proposed explorations will yield results as expected, and that general business and economic conditions will not change in a material adverse manner. Although ATHA has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

    Such statements represent the current view of ATHA with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by ATHA, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Risks and uncertainties include, but are not limited to the following: inability of ATHA to realize the benefits anticipated from the exploration and drilling targets described herein or elsewhere; in ability of ATHA to complete current exploration plans as presently anticipated or at all; inability for ATHA to economically realize on the benefits, if any, derived from the exploration program; failure to complete business plans as it currently anticipated; overdiversification of ATHA’s portfolio; failure to realize on benefits, if any, of a diversified portfolio; unanticipated changes in market price for ATHA shares; changes to ATHA’s current and future business and exploration plans and the strategic alternatives available thereto; growth prospects and outlook of the business of ATHA; and the ability to advance the Company projects and its proposed exploration program; risks inherent in mineral exploration including risks related worker safety, weather and other natural occurrences, accidents, availability of personnel and equipment, and other factors; aboriginal title; failure to obtain regulatory and permitting approvals; no known mineral resources/reserves; reliance on key management and other personnel; competition; changes in laws and regulations; uninsurable risks; delays in governmental and other approvals, community relations; stock market conditions generally; demand, supply and pricing for uranium; and general economic and political conditions in Canada, Australia and other jurisdictions where ATHA conducts business. Other factors which could materially affect such forward-looking information are described in the filings of ATHA with the Canadian securities regulators which are available on ATHA’s profile on SEDAR+ at www.sedarplus.ca. ATHA does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

    SOURCE: ATHA Energy Corp

    View the original press release on ACCESS Newswire

  • Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management

    Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management

    Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility

    Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028

    CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds (Ares), a leading global alternative investment manager, to increase flexibility.

    The non-dilutive debt financing consists of three tranches over five years, including:

    • A $600 million initial term loan funded at closing

    • A $400 million delayed draw term loan facility (DDTL), available in multiple draws at Moderna’s discretion through November 2027

    • An additional $500 million DDTL, available in multiple draws at Moderna’s discretion through November 2028. This tranche is contingent on the achievement of key regulatory milestones aligned with Moderna’s late-stage clinical pipeline

    “While we remain well-positioned to achieve our 2028 cash breakeven target, this additional capital enhances our strong balance sheet and enables increased flexibility over the coming years,” said Jamey Mock, Chief Financial Officer of Moderna. “Ares is a highly reputable lender in the healthcare space, and we are proud to have their valuable financial backing in pursuit of our long-term financial targets.”

    “We are pleased to provide flexible capital to Moderna at this pivotal moment in their growth trajectory,” said Doug Dieter, DrPH, Co-Head of Ares Specialty Healthcare. “Moderna has already demonstrated the power of its mRNA platform with multiple commercial products and has an impressive and differentiated clinical pipeline. This investment reflects Moderna’s disciplined approach to capital management and our support of their long-term financial strategy.”

    Moderna will host its Analyst Day event for investors at 9:00 a.m. ET on November 20, 2025. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Moderna website: https://investors.modernatx.com/. A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.

    About Moderna

    Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

    With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s credit facility with Ares; Moderna’s financial condition and operational flexibility; Moderna’s 2025 financial guidance; Moderna’s 2028 cash breakeven target; and Moderna’s ability to achieve key regulatory milestones aligned with its late-stage pipeline and to draw on future tranches. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts

    Media:

    Chris Ridley
    Head of Global Media Relations
    +1 617-800-3651
    Chris.Ridley@modernatx.com

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire

  • Nashville Lavender Pioneer Gigi de Lugo Secures Majority Ownership of Permanent Farm in Joelton, Tennessee

    Nashville Lavender Pioneer Gigi de Lugo Secures Majority Ownership of Permanent Farm in Joelton, Tennessee

    Nashville, TN November 20, 2025 –(PR.com)– A fourth-generation U.S. Virgin Islander who has called Nashville home since 1993, de Lugo transitioned from an award-winning career in music publishing and feature film producing, with Platinum and Gold Albums, Arista Records A-Team Award, BMI #1 and more, to lavender farming in 2018. Focusing exclusively on Peace Tree Farm’s trademarked, heat- and humidity-tolerant hybrids—Lavender Phenomenal®, Sensational!®, and Exceptional!®—she has proven these cultivars are the definitive choice for Southern growers.

    Lloyd Traven, President of Peace Tree Farm, the original breeder of these global-standard varieties, praises de Lugo’s early foresight and influence:

    “Over a period of the last decade, Gigi has been highlighting our introductions that have become the Gold Standard for lavender worldwide, and she was an early proponent because she saw the extra value of these introductions… Once she knew the plants were different and far superior, she committed to making the right choice for her customers. She can now proudly say that she has started over 30 new farms on their journey across an area ranging from Virginia through to Iowa!”

    From its original rented fields in Whites Creek—Gigi’s Lavender, was celebrated by “Garden & Gun” magazine as one of the South’s top lavender destinations—the licensed nursery has supplied thousands of Peace Tree-bred plants throughout Tennessee and beyond. In 2019, de Lugo founded “The Lavender Exchange (TLx),” an exclusive membership alliance offering ongoing technical support, resource sharing, cooperative marketing, and agritourism promotion to farms that source their plants exclusively from Gigi’s Nursery.

    Traven also highlights the impact of this network: “Gigi also knows the great importance and value of marketing with expression of clear benefits and a clear message. She created the Lavender Exchange with this in mind—to provide an outlet for cooperative marketing and sharing of equipment and machinery and product ideas.”

    This strengthened ownership ensures continuity for de Lugo’s research, educational outreach, and product innovation at the Joelton location, including her newest Patent Pending offering, “ZWave Mg”—a topical magnesium spray infused with pure Phenomenal lavender hydrosol steam-distilled exclusively from flowers grown by TLx member farms. Designed for relaxation, muscle relief, and better sleep, ZWave Mg showcases the wellness potential of Southern-grown lavender.

    “This milestone gives us the stability and security to continue investing in our Southern lavender research, development, product distribution, and growing community of the farms we support through The Lavender Exchange (TLx),” said Gigi de Lugo. “From the beginning I set out to prove lavender could become a viable cash crop for Tennessee and Southern farms—not only a pretty agritourism field, but a real harvestable commodity built on Phenomenal®. It took courageous pioneers willing to bet on the unproven and stay the course with me. These years, alongside the extraordinary farmers of our TLx family, have been one of the greatest adventures of my life.”

    Experience the pure essence of Southern lavender: Gigi’s premium products, including the breakthrough ZWave Mg, are available exclusively through her website, and retail partners across Tennessee. Gigi is in discussion with a Nashville based manufacturer to expand her ZWave Mg production capacity for 2026.

    About Gigi’s Lavender Nursery & Farm
    Gigi’s Lavender Nursery & Farm is a Tennessee-licensed grower and an exclusive Southeast source for Peace Tree Farm’s Phenomenal®, Sensational!®, Exceptional!®, Inspirational!® lavender cultivars. It serves as headquarters for The Lavender Exchange (TLx), a premier network advancing lavender agriculture and agritourism across the South and Midwest.

    Contact Information:
    TLx The Lavender Exchange
    Gigi de Lugo
    615-422-5083
    Contact via Email
    thelavenderexchange.com
    Office: 615-422-5083

    Read the full story here: https://www.pr.com/press-release/954122

    Press Release Distributed by PR.com

  • Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update

    Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update

    TAMPA, FL / ACCESS Newswire / November 20, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader at the nexus of serialization of healthcare technology infrastructure into the individual patient fulfillment of prescription drug through pharmacies ‘From Manufacturer To Patient’, today reported financial results for the period ended September 30, 2025 on Form 10-Q on November 19, 2025[1] and provided a business update from the CEO.

    “The last 6 weeks have really allowed me to understand the different stages of development of the various parts of the business after I was reappointed as President and given the title of Interim-CEO on October 6, 2025,” said Prashant Patel, RPh, President and Interim-CEO of Wellgistics Health. “We have centered the primary focus of our sales team on the launch of Brenzavvy® for the Type 2 diabetes market. Type 2 diabetes affects over 33 million Americans[2] with only a small portion of patients getting access a SGLT-2 inhibitor drug primarily to out-of-pocket cost constraints. We have developed a program to significantly reduce these out-of-pocket costs for patients using our EinsteinRx™ AI pharmacy hub software, and expect this product launch may contribute meaningfully to our future revenue growth if successfully commercialized. One of the brightest spots in my review has been the tremendous work done over the last 6 months by our technology team led by Chief Technology Officer Srini Kalla to finalize EinsteinRx and make it ready for launch. The ability of our tech team to help implement our software seamlessly for our clients will be crucial for our long-term success and I now have great confidence in Srini’s ability to meet the growth challenge we expect to face.”

    Mr. Patel continued, “While the third quarter saw significant equity-based expenses tied to the pre-IPO acquisition of our pharmaceutical distribution business unit, we have begun to rationalize our go forward approach and it will be centered on the staged integration of EinsteinRx throughout our customers’ value chains. As we prepare to move into 2026 when we intend to put EinsteinRx onto the PharmcyChain™ smart contracts platform we expect to create, we believe there is a meaningful opportunity to optimize the way healthcare information is processed, exchanged and validated. By giving us better data to feed into our models, we intend to further optimize outcomes for patients while delivering cost reduction for payers. We are in advanced discussions to to complete the license agreement underpinning our blockchain smart contracts strategy with DataVault AI (NASDAQ:DVLT) in the fourth quarter of 2025 or the first quarter of 2026 in order to secure the opportunity-enabling intellectual property protection around which we will execute upon our roadmap to disrupt healthcare through efficiency.”

    “While our primary business is in the $634 billion US prescription drug market[3], an increasing portion of U.S. discretionary healthcare spend is going into the $2 trillion US Wellness Market[4]. Telehealth providers now account for 17% GLP-1 US prescriptions[5], which created the rationale for our proposed acquisition of Kare Hub Rx for its optimized ‘plug & play’ telepharmacy integration software that seamlessly allows telehealth providers to route prescriptions through our online pharmacy.”

    “In order to create a competitive edge in our GLP-1 offering business to pharmacies and telehealth companies, in March we partnered with Tollo Health to provide prescription-complementary products to address major GLP-1 side effects with their products soon becoming commercially available in the United States. The GLP-1 drug market currently sits at $53 billion annually according to Grandview Research and expected to reach $156 billion by 2030[6], currently dominated by Eli Lilly and Novo Nordisk, with various injection and oral formulations that all carry muscle loss side effects. Our goal is to eventually offer all GLP-1 drugs to pharmacy clients and through our online pharmacy at competitive prices, while selling cash-pay side effect-mitigating medical foods that we believe provide a more comprehensive solution than our competitors, while increasing margins per GLP-1 prescription.”

    “We expect our first GLP-1 side effect product that helps to mitigate muscle loss will launch in the first quarter of 2026. Additionally, we have begun distributing 3CL protease inhibitor cleansing supplement Tollovid™ targeting Long COVID to certain physicians. In 2024, the CDC reported that over 17 million Americans were living with Long COVID[7]. We expect certain Long COVID clinicians to begin making Tollovid available for their patients this month. We also plan to launch the first natural antiviral combo Tollovid and Galectovid™ to pharmacies after Thanksgiving. We intend to expand our prescription drug catalog to include drugs frequently prescribed for Long COVID in order to develop a full package for pharmacies.”

    Mr. Patel completed, “Lastly, the previously disclosed acquisition of Peek Healthcare Technologies, Inc. has been terminated as it is no longer strategically aligns with our plans for the future.”

    Financial Results
    The Company recorded a net operating loss of $33.878 million in the third quarter of 2025, compared with a net operating loss of $1.867 million in the third quarter of 2024. The increase in net loss was largely due to increased stock-based compensation. Net loss per share in the third quarter of 2025 was $0.46 on 74.379 million weighted average shares outstanding, compared to third quarter of 2024 where the Company delivered a net loss of $0.04 per share on 48.403 million weighted average shares outstanding.

    About Wellgistics Health, Inc.
    Wellgistics Health (NASDAQ:WGRX) is pharmacy physical and technology enabling health IT company that specializes in optimizing the delivery medications from manufacturers to patients. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

    For more information, visit www.wellgisticshealth.com.

    Forward-Looking Statements
    This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

    Media & Investor Contact
    Media:
    media@wellgisticshealth.com

    Investor Relations:
    IR@wellgisticshealth.com

    Investor Relations Contact
    Skyline Corporate Communications Group, LLC
    Scott Powell, President
    1177 Avenue of the Americas, 5th Floor
    New York, NY 10036
    Office: (646) 893-5835
    Email: info@skylineccg.com

    SOURCE: Wellgistics Health, Inc.

    View the original press release on ACCESS Newswire

  • OK! Magazine Features SHEGLAM’s Commitment to Safety and Ethical Beauty Standards

    OK! Magazine Features SHEGLAM’s Commitment to Safety and Ethical Beauty Standards

    SINGAPORE, SG – November 20, 2025 – PRESSADVANTAGE –

    Leading entertainment and lifestyle publication OK! Magazine recently featured SHEGLAM in an in-depth article exploring the brand’s commitment to ethical values and transparency in the beauty industry. Published on November 6, 2025, the article titled “Inside SHEGLAM’s Mission to Create a More Ethical Beauty Industry” examines how the cosmetics brand addresses consumer questions like “is SHEGLAM safe” through its dedication to safety, quality, and ethical practices since its founding in 2019 by Sylvia Fu.

    The OK! Magazine feature provides insights into the brand’s safety standards and transparent practices for those wondering “is SHEGLAM safe.” The article details how SHEGLAM has grown from a small, intimate team to a brand now available in over 150 countries and 7,000 retail locations worldwide.

    At the heart of the brand’s approach to product safety lies its dedication to global regulatory compliance. OK! Magazine highlights that every SHEGLAM formula meets or exceeds the safety and quality standards established by various regions around the world, including the United States, the European Union, the Middle East, and Latin America. This approach to regulatory compliance ensures that consumers in different markets can trust that the products they purchase have been formulated with their safety as the top priority.

    The OK! Magazine article emphasizes SHEGLAM’s proactive approach to ingredient safety, noting that the brand’s team actively researches and bans substances that could be environmentally harmful, including phthalates, parabens, formaldehyde donors, and PFAS. Each product undergoes several stages of formula optimization and testing to protect consumer health.

    Transparency represents one of the most critical commitments at SHEGLAM, according to the OK! Magazine feature. The article points out that every SHEGLAM package and online listing includes a complete ingredient list, allowing consumers to make informed choices before purchasing a product. This level of transparency is particularly important in today’s beauty landscape, where consumers are increasingly demanding to know exactly what they’re putting on their skin.

    Beyond product formulations, the OK! Magazine article explores how SHEGLAM’s dedication to quality and ethics extends throughout its entire supply chain. For those questioning “is SHEGLAM safe,” the brand’s supplier partnerships provide additional assurance. SHEGLAM exclusively partners with suppliers that hold certifications under Good Manufacturing Practices and Environmental Management Systems. These certifications help ensure that every step in the production line meets high standards for product safety, hygiene, and sustainability.

    The feature highlights that ethical responsibility is an underlying component in SHEGLAM’s manufacturing process. Suppliers adhere to international labor conventions, including those established by the International Labour Organization (ILO). Independent parties conduct audits to verify compliance with labor, health, and environmental standards, with over half of SHEGLAM’s suppliers participating in EcoVadis assessments that quantify their progress in social and ecological performance.

    OK! Magazine also spotlights SHEGLAM’s commitment to sustainability and environmental responsibility. The brand’s packaging focuses on minimizing waste through thoughtful material selection. Every box is created from 100% FSC-certified paper, while glass and aluminum components are used throughout the product line to reduce plastic consumption.

    The article emphasizes SHEGLAM’s cruelty-free commitment, noting that the brand holds Leaping Bunny certification from Cruelty Free International, the global gold standard for cruelty-free certified products. This certification demonstrates SHEGLAM’s stance that no beauty products should come at the expense of animal welfare.

    OK! Magazine’s coverage of SHEGLAM comes at a time when beauty consumers are increasingly seeking transparency and accountability from cosmetic brands. The article examines the brand’s safety protocols, supply chain practices, and sustainability initiatives, from its viral Color Bloom Liquid Blush to its brand collaborations, offering readers a comprehensive look at how SHEGLAM is addressing consumer concerns about product safety and ethical responsibility in the beauty industry.

    About SHEGLAM: Founded in 2019 by Sylvia Fu, SHEGLAM is an inclusive beauty brand offering high-quality makeup and affordable cruelty-free cosmetics. SHEGLAM is certified 100% Cruelty-Free with Leaping Bunny certification. The brand has garnered recognition from beauty media platforms including Bustle Beauty, NYLON Beauty, Who What Wear, and Cosme Japan.

    ###

    For more information about SHEGLAM, contact the company here:

    SHEGLAM
    SHEGLAM Media Team
    contact@sheglam.com

  • Cool Blew Inc. Expands Emergency HVAC and Solar Services

    Cool Blew Inc. Expands Emergency HVAC and Solar Services

    Peoria, AZ – November 19, 2025 – PRESSADVANTAGE –

    Cool Blew Inc., a Peoria-based HVAC and solar services provider, announces expanded round-the-clock emergency response capabilities for both heating and cooling systems and solar installations throughout the greater Phoenix metropolitan area. The expansion addresses growing demand for immediate technical support as extreme weather events and power grid challenges increase across Arizona.

    The company, which has served Arizona communities since 2002, reports an increase in emergency HVAC in Peoria service calls over the past year, particularly during peak summer months when temperatures regularly exceed 110 degrees Fahrenheit. The expanded emergency services now cover residential and commercial properties across Peoria, Surprise, Phoenix, Glendale, Sun City, Sun City West, Scottsdale, Mesa, Gilbert, Tempe, and Chandler.

    “Arizona homeowners and businesses face unique challenges with both traditional HVAC systems and solar installations due to our extreme climate conditions,” said Scott Proctor, Operations Manager at Cool Blew Inc. “When air conditioning fails during a heat wave or solar panels malfunction during peak production hours, immediate response becomes critical for safety and comfort. Our expanded emergency services ensure that residents have access to qualified technicians when they need them most.”

    The company’s emergency response team handles various critical situations, from complete system failures to partial malfunctions affecting energy efficiency. Besides HVAC services, technicians address refrigerant leaks, compressor failures, electrical issues, and thermostat malfunctions. The solar division provides emergency solar repair services for inverter failures, panel damage from storms, wiring issues, and monitoring system problems.

    Cool Blew Inc. maintains a fleet of fully equipped service vehicles and stocks commonly needed replacement parts to minimize repair time during emergency calls. Technicians receive ongoing training on the latest HVAC technologies and solar systems from leading manufacturers, ensuring they can service all major brands and models.

    The expansion comes as Arizona experiences continued population growth and increased adoption of solar energy systems. According to industry data, the state ranks among the top five nationally for installed solar capacity. The state also ranks high in annual HVAC service demands. This dual expertise positions Cool Blew Inc. to address the interconnected needs of modern home energy systems.

    “We recognize that many homeowners now rely on integrated systems where HVAC and solar components work together for optimal energy efficiency,” added Proctor. “Our technicians understand these connections and can diagnose issues that might affect both systems simultaneously, providing comprehensive solutions rather than temporary fixes.”

    Cool Blew Inc. is a family-owned and operated company providing air conditioning, heating, plumbing, and solar services throughout the Phoenix metropolitan area. As a factory-authorized dealer for major HVAC brands, the company offers installation, repair, and maintenance services for residential and commercial properties. The company also specializes in energy-saving solutions, including insulation, duct sealing, and solar panel installation, helping Arizona residents reduce utility costs while maintaining indoor comfort.

    ###

    For more information about Cool Blew Inc., contact the company here:

    Cool Blew Inc.
    Scott Proctor
    623-872-2900
    scott@coolblew.com
    8927 W Bloomfield Rd #135, Peoria, AZ 85381

  • Emergency Dentist East Dulwich Announces Treatment Consultations at The Gardens Dental Centre (Smile 4 U)

    Emergency Dentist East Dulwich Announces Treatment Consultations at The Gardens Dental Centre (Smile 4 U)

    London, England – November 19, 2025 – PRESSADVANTAGE –

    The Gardens Dental Centre (Smile 4 U) has announced the availability of dedicated consultations for patients seeking urgent dental care in East Dulwich, offering local residents a clear route to professional assessment when unexpected dental problems arise. The practice aims to handle unexpected enquiries relating to sudden pain, accidental damage, and oral discomfort that cannot be postponed, prompting the team to formalise a consultation pathway that helps patients understand what emergency dental treatment may involve and how quickly they can be seen.

    Many people remain unsure about what qualifies as a dental emergency, which can often delay them from seeking help at an appropriate time. Common issues include severe toothache, persistent bleeding, fractured or knocked-out teeth, swelling that affects eating or speaking, and damage following an accident.

    Emergency Dentist East Dulwich - The Gardens Dental Centre (Smile 4 U)

    These situations can leave patients uncertain about the next step, particularly if the problem develops outside of their usual routine appointments. The Gardens Dental Centre (Smile 4 U) aims to provide clarity through focused consultations that explain the nature of the concern, outline likely treatment options, and identify whether immediate intervention is required. More information about dental emergencies and how consultations are arranged can be found here: https://smile4u.co.uk/dentist-east-dulwich-london/general-dentistry/dental-emergencies/.

    The launch of these emergency-focused consultations also sits alongside the broader offering at the practice, which continues to welcome patients for routine and planned dental care. The Gardens Dental Centre (Smile 4 U) offers a wide range of treatments to support long-term oral health for individuals and families across East Dulwich. Patients attending for routine checkups, restorative procedures, preventive care, and cosmetic treatments will still benefit from the familiar approach the practice has built over the years, centred on communication and clear guidance.

    For those who may require emergency attention, the new consultation structure ensures they can receive practical advice and a clinical evaluation without uncertainty about how the process works. Details of the wider range of dental treatments available at the practice are available here: https://smile4u.co.uk/dentist-east-dulwich-london/.

    These newly announced consultations provide an opportunity to speak directly with a dental professional about the symptoms that prompted concern. During the appointment, the clinician assesses the affected area, discusses when the issue first appeared, and reviews any factors that might complicate the treatment plan.

    Patients can expect the conversation to cover immediate next steps, including whether urgent care is recommended, whether further diagnostic checks may be helpful, and what types of treatment could be appropriate depending on the findings. The intention is to make the experience straightforward, giving patients a clear understanding of what is happening and how to move forward without delay.

    The Gardens Dental Centre (Smile 4 U) has emphasised that these consultations are not intended solely for severe emergencies. They are also suitable for people who are unsure whether their symptoms require urgent care, such as intermittent discomfort, minor chips, or swelling that appears suddenly. By offering structured guidance in these early stages, the practice aims to prevent issues from progressing and to reassure patients who may be uncertain about the seriousness of their situation.

    Alongside emergency dental support and the practice’s established offering, residents can also access information through an additional online resource, which directs patients towards further guidance on finding care in East Dulwich. This web page outlines information about the practice location and the route planning instructions. Readers interested in this information can visit this link: https://gotothis.one/dentist-east-dulwich-london.

    The Gardens Dental Centre (Smile 4 U) maintains that the introduction of dedicated emergency consultations is aimed at strengthening patient access to timely, reliable care. With growing awareness of the importance of addressing dental issues early, the practice anticipates that the structured approach will help residents feel more supported when unexpected problems interrupt their day.

    ###

    For more information about The Gardens Dental Centre (Smile 4 U), contact the company here:

    The Gardens Dental Centre (Smile 4 U)
    Maryam Shahid
    +44-20-8693-4001
    info@thegardensdentalcentre.co.uk
    The Gardens Dental Centre (Smile 4 U), 44B The Gardens, London SE22 9QQ, United Kingdom

  • Efficient Roofing Emphasizes Emergency Safety and Compliance Standards for Ongoing Roofing Projects

    Efficient Roofing Emphasizes Emergency Safety and Compliance Standards for Ongoing Roofing Projects

    GILBERT, AZ – November 19, 2025 – PRESSADVANTAGE –

    Efficient Roofing, an Arizona-based roofing contractor, has reinforced its commitment to maintaining rigorous safety and compliance standards across all commercial and residential roofing projects throughout the state. The company’s emphasis on safety protocols comes as severe weather patterns continue to impact commercial properties across the Phoenix metropolitan area and surrounding communities.

    The roofing contractor has implemented enhanced safety measures and compliance protocols designed to protect both workers and property owners during routine maintenance and emergency repair situations. These standards apply to all service areas, including emergency commercial roofing in Phoenix and surrounding municipalities where the company maintains operations.

    “Safety and compliance are fundamental to every project we undertake, whether it’s a scheduled commercial roof replacement or an urgent repair situation,” said Justin Loflin, owner of Efficient Roofing. “Our teams follow strict protocols that meet or exceed industry standards, ensuring that every job is completed safely and effectively while minimizing disruption to business operations.”

    The company’s safety initiatives encompass comprehensive training programs for all technicians, regular equipment inspections, and adherence to Occupational Safety and Health Administration guidelines. These measures are particularly critical during emergency response situations, where rapid deployment must be balanced with proper safety procedures.

    Efficient Roofing’s service capabilities extend across multiple roofing systems, including tile, metal, foam, and shingle installations. The company provides specialized commercial services such as TPO roofing systems, steel roofing, and roof coatings with waterproofing applications. Each service category maintains specific safety protocols tailored to the unique requirements of different roofing materials and installation methods.

    The contractor’s emergency response team remains available around the clock to address urgent roofing issues that can arise from storm damage, unexpected leaks, or structural concerns. This includes emergency roofing in Gilbert and other communities throughout Arizona, where severe weather can create immediate threats to commercial and residential properties.

    “Maintaining readiness for emergencies while upholding safety standards requires ongoing training and investment in proper equipment,” added Loflin. “Our technicians participate in regular safety briefings and certification programs to ensure they can respond effectively to any roofing challenge while protecting themselves and our clients’ properties.”

    The company’s commitment to safety extends to its warranty programs, which can span up to 50 years for qualifying installations. These comprehensive warranties reflect the confidence Efficient Roofing places in its workmanship and adherence to proper installation procedures.

    Efficient Roofing serves communities across Arizona, including Phoenix, Chandler, Gilbert, Scottsdale, Mesa, Tempe, Peoria, Glendale, and numerous other municipalities. The company specializes in both residential and commercial roofing services, offering solutions ranging from routine maintenance to complete roof restoration projects. With expertise in multiple roofing systems and a focus on quality materials and craftsmanship, Efficient Roofing continues to serve as a trusted resource for property owners throughout Arizona.

    ###

    For more information about Efficient Roofing, contact the company here:

    Efficient Roofing
    Justin Loflin
    480-671-5769
    info@efficientroofingaz.com
    636 W Commerce Ave, Gilbert, AZ 85233

  • Lucid Leverage LLC Expands White-Label SEO Resellers Program to Meet Rising Agency Demand

    Lucid Leverage LLC Expands White-Label SEO Resellers Program to Meet Rising Agency Demand

    Tempe, AZ – November 19, 2025 – PRESSADVANTAGE –

    Lucid Leverage LLC, a digital marketing agency specializing in search engine optimization and online reputation management, today announced the expansion of its white-label SEO reseller program in response to increased demand from marketing agencies seeking to scale their service offerings without adding in-house technical staff.

    The Los Angeles-based company has seen a significant uptick in partnership inquiries from agencies looking to offer comprehensive SEO services under their own brand. The expanded program provides partner agencies with fully customizable SEO solutions, including local search optimization, reputation management, and detailed performance reporting that can be branded with partner logos and contact information.

    Recent industry data indicates that small to mid-sized marketing agencies increasingly rely on white-label partnerships to compete with larger firms while maintaining lean operational structures. This trend has accelerated as businesses across all sectors prioritize digital visibility and search engine rankings in their marketing strategies.

    “The landscape of digital marketing has fundamentally shifted over the past few years, with more agencies recognizing that partnering with SEO resellers allows them to focus on client relationships while we handle the technical execution,” said Chris Quintela, founder of Lucid Leverage. “Our expanded program addresses the specific pain points agencies face when trying to deliver consistent SEO results without the overhead of maintaining specialized teams.”

    The white-label program encompasses a comprehensive suite of services including local SEO campaigns, press release distribution, social media management, web design, and YouTube marketing optimization. Partner agencies can select services based on their clients’ needs while maintaining complete control over pricing and client communication.

    A key differentiator of the program is its emphasis on transparency and education. Partner agencies receive detailed monthly reports that explain not just what was done, but why specific strategies were implemented and how they contribute to overall search visibility. This approach enables partners to have informed conversations with their clients about SEO progress and strategy.

    “We’ve structured our reseller program to be more than just a service provider relationship,” added Quintela. “Partners gain access to our expertise and can leverage our proven methodologies to build their own reputation as full-service digital marketing providers. This creates sustainable growth opportunities for agencies of all sizes.”

    The expansion comes at a time when search engine algorithms continue to evolve, making it increasingly challenging for businesses to maintain visibility without specialized expertise. By partnering with established providers, agencies can offer sophisticated SEO strategies that adapt to these changes while focusing their internal resources on client acquisition and retention.

    Lucid Leverage LLC has been providing digital marketing services since its founding, with a focus on measurable results and long-term client success. The company specializes in helping businesses increase their online visibility through strategic search engine optimization, social media management, and reputation management services. Based in Los Angeles with operations in Tempe, Arizona, Lucid Leverage maintains accreditation with the Better Business Bureau and serves clients across various industries nationwide.

    ###

    For more information about Lucid Leverage LLC, contact the company here:

    Lucid Leverage LLC
    Chris Quintela
    480-269-4544
    cq@lucidleverage.com
    60 E. Rio Salado Pkwy 9th Floor Suite 313
    Tempe, AZ 85281